San Anselmo Resident, a Genetic Carrier of ALS, Fights to Cure the Disease

San Anselmo resident, a genetic carrier of ALS, fights to cure the disease

San Anselmo resident Mindy Uhrlaub, left, pictured with her mom. (Courtesy of Mindy Uhrlaub)(Courtesy of River Grove Books)Show Caption1 of 2San Anselmo resident Mindy Uhrlaub, left, pictured with her mom. (Courtesy of Mindy Uhrlaub)Expand When Mindy Uhrlaub got tested to see if she was a carrier of the fatal mutation that causes the amyotrophic lateral sclerosis (ALS) her mom had, her neurogeneticist at Stanford told her that if she was negativ…

Gene therapy may slow loss of motor function in ALS

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic lateral sclerosis (ALS), offering new hope for treating the devastating neurodegenerative disease.

NeuroSense Therapeutics Advances Toward Canadian Fast-Track Approval for ALS Drug PrimeC

NeuroSense Therapeutics (NASDAQ: NRSN) has reached a significant milestone in its quest to bring PrimeC, its lead ALS drug candidate, to market, following a constructive pre-submission meeting with Health Canada. This meeting explored the drug’s eligibility for Canada’s fast-track approval pathway, known as the Notice of Compliance with Conditions (NOC/c), potentially expediting PrimeC’s availability to Canadian ALS patients. The positive outcom…

Longitude Prize on ALS to award £7.5m to AI drug target discoveries for common form of MND - THIIS Magazine

The Longitude Prize on ALS, a new £7.5 million global challenge prize, has launched to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral sclerosis), the most common form of MND (motor neurone disease). ALS is a progressive neurodegenerative disease that damages the nerves in the brain and spinal cord (called motor neurones). Signals from the brain stop reaching muscl…

Gene Therapy May Slow Loss of Motor Function in ALS, Penn and CHOP Research Finds

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic lateral sclerosis (ALS), offering new hope for treating the devastating neurodegenerative disease. "Silencing” a gene associated with regulating TDP-43, the protein that accumulates in the brain and causes ALS, with a technique called RNA interference (RNAi) allowed mice to survive an average of 54 percent longer. Subjects

ALS: how close are we to a cure?

Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years. The post ALS: how close are we to a cure? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is…